Geneoscopy

Colorectal cancer rates (CRC) for adults under 50 have surged 50% since the 1990s. 62% of young-onset CRC survivors have no family history, and 71% of young-onset cases are diagnosed at Stage III or IV. Colorectal cancer has a greater than 90% survival rate when caught early. And yet, only 20% of 45 to 49-year-olds are getting screened. Learn and share: https://bit.ly/3YAqz3Z Geneoscopy's FDA-approved ColoSense test demonstrated 100% sensitivity for CRC and 44% sensitivity for advanced adenomas, considered precursors to the disease in average-risk individuals, ages 45-49. For more about ColoSense visit: https://bit.ly/3W9RfH7 #ScreeningSavesLives #EarlyDetection #45istheNew50 #GetScreened Colorectal Cancer Alliance

AS PUBLISHED IN THE JOURNAL OF MOLECULAR DIAGNOSTICS: #OpenAccess article: Analytical Validation of the Multitarget Stool RNA Test for Colorectal Cancer Screening. Authors from Geneoscopy Washington University School of Medicine in St. Louis and WashU Pathology & Immunology https://lnkd.in/eTbsm-HR. Full #OpenAccess text:

More great resources from our allies in advocacy at Colon Cancer Coalition! Thank you! #knowledgeispower #selfcareishealthcare #prevention #earlydetection

Great news for patients! Congress added $1M to the CDC IBD programs budget—the largest increase since 2021. Let's keep moving toward cures! Crohn's & Colitis Foundation #IBD #advocacyworks #GIHealth #patientsfirst

Colorectal cancer (CRC) is the second deadliest cancer in the U.S. However, millions of eligible Americans do not get screened due to a lack of access to or avoidance of invasive screening options like colonoscopies. The rates of CRC incidence among younger populations under 50 years old is also on the rise. ColoSense, Geneoscopy's FDA-approved at home screening test indicated for adults, ages 45 and over, who are at a typical risk for developing CRC, uses an innovative and proprietary RNA-based platform to screen for CRC and advanced adenomas. Learn more at: https://bit.ly/3W9RfH7

We are excited to share that Geneoscopy has received the St. Louis INNO's Fire Award! The Fire Awards recognize innovators shaping the entrepreneurial ecosystem and applaud companies and organizations growing their teams, launching new products, and positively impacting society and the community. We are honored to be acknowledged for our commitment to advancing gastrointestinal health through pioneering solutions like ColoSense™, our noninvasive RNA biomarker colorectal cancer screening test. Congratulations to all the Fire Award winners and nominees. We are thankful to be a part of such an amazing community. We extend our gratitude to St. Louis Inno and sponsors, Anders CPAs + Advisors, Arch Grants and Greater St. Louis, Inc., as well as our dedicated team, partners, and supporters, for believing in our mission. #INNOFireAwards #HealthcareInnovation #Geneoscopy #ColorectalCancer #STLMade

FOR IMMEDIATE RELEASE: Geneoscopy is pleased to announce the publication of a study in The Journal of Molecular Diagnostics, highlighting the analytical validation of ColoSense, a noninvasive, multi-target stool RNA (mt-sRNA) screening test for colorectal cancer and advanced adenomas in average-risk individuals aged 45 and older. This study highlights ColoSense's high stability, precision, and reproducibility. Read the full release here: https://bit.ly/4cAIA66

Dr. Kimmie Ng, Associate Professor of Medicine at Harvard Medical School and Founding Director of Dana-Farber Cancer Institute's Young-Onset Colorectal Cancer Center, discusses the increase in colorectal cancer among those under 50 and emphasizes the need for awareness, early detection, and proactive healthcare strategies. Learn more: https://bit.ly/4eR7wb9

Happy 4th of July from Geneoscopy! As we celebrate our nation's independence, let's also celebrate the freedom to live vibrant and healthy lives. Early detection through colorectal cancer screening can help ensure brighter tomorrows for all. Enjoy the festivities, stay safe, and take care of yourself and your loved ones! #IndependenceDay #Wellness #GeneoscopyCares

Exciting news! The Crohn's & Colitis Foundation unveiled its new five-year research agenda, a strategic roadmap developed to set research priorities in inflammatory bowel disease (IBD) not only for the Foundation, but for the entire IBD research community. Read the latest: https://bit.ly/4cBIvif Beyond colorectal cancer, Geneoscopy, in partnership with leading universities and biopharmaceutical companies, is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas, including IBD. We're committed to improving patient outcomes and driving progress in IBD diagnostics. Learn more about our work: https://bit.ly/3VHRuJl #Geneoscopy #IBDResearch #HealthcareInnovation #CrohnsDisease #UlcerativeColitis #RNABiomarker@